Clinical Trial Update: Study of Interest of Personalized Radiotherapy Dose Redistribution in Patients With Stage III NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating personalized radiotherapy dose redistribution for stage III non-small cell lung cancer has completed enrollment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Centre Henri Becquerel | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED